N-(1-adamantyl)-6-cyclopropyl-1-(2,4-dichlorophenyl)-4H-indeno[2,1-d]pyrazole-3-carboxamide
C30H29Cl2N3O — CID 127030117
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(1-adamantyl)-6-cyclopropyl-1-(2,4-dichlorophenyl)-4H-indeno[2,1-d]pyrazole-3-carboxamide
N-(1-adamantyl)-6-cyclopropyl-1-(2,4-dichlorophenyl)-4H-indeno[2,1-d]pyrazole-3-carboxamide (PubChem CID 127030117) has the molecular formula C30H29Cl2N3O and a molecular weight of 518.49 g/mol. Its IUPAC name is N-(1-adamantyl)-6-cyclopropyl-1-(2,4-dichlorophenyl)-4H-indeno[2,1-d]pyrazole-3-carboxamide.
Molecular Properties
| Compound Name | N-(1-adamantyl)-6-cyclopropyl-1-(2,4-dichlorophenyl)-4H-indeno[2,1-d]pyrazole-3-carboxamide |
|---|---|
| PubChem CID | 127030117 |
| Molecular Formula | C30H29Cl2N3O |
| Molecular Weight | 518.49 g/mol |
| Exact Mass | 517.17 |
| IUPAC Name | N-(1-adamantyl)-6-cyclopropyl-1-(2,4-dichlorophenyl)-4H-indeno[2,1-d]pyrazole-3-carboxamide |
| SMILES | O=C(NC12CC3CC(CC(C3)C1)C2)c1nn(-c2ccc(Cl)cc2Cl)c2c1Cc1cc(C3CC3)ccc1-2 |
| InChI | InChI=1S/C30H29Cl2N3O/c31-22-4-6-26(25(32)12-22)35-28-23-5-3-20(19-1-2-19)10-21(23)11-24(28)27(34-35)29(36)33-30-13-16-7-17(14-30)9-18(8-16)15-30/h3-6,10,12,16-19H,1-2,7-9,11,13-15H2,(H,33,36) |
| InChIKey | KETMMCIOZHJPQM-UHFFFAOYSA-N |
| XLogP | 7.33 |
| TPSA | 46.92 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 518.49 |
| LogP ≤ 5 | 7.33 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 127030117 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.